Dr. Vogelzang Discusses First-Line Axitinib in mRCC
Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.
Are We Approaching a Fourth Generation of Therapies for Metastatic Kidney Cancer?
Drs. Rini and Bukowski do an excellent job of updating and commenting on the rapidly evolving field of therapy for metastatic renal cell carcinoma (RCC).
2 Clarke Drive Cranbury, NJ 08512